ERCC6 sirna

ERCC6 siRNA (Human)

Cat. Num. AAA8206560

• Gene Names: ERCC6; CSB; CKN2; COFS; ARMD5; COFS1; RAD26; UVSS1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: ERCC6; ERCC6 siRNA (Human); CSB; DNA excision repair protein ERCC-6; ATP-dependent helicase ERCC6; Cockayne syndrome protein CSB; ERCC6 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: ERCC6 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1,493

• Applicable Applications for ERCC6 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human ERCC6 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for ERCC6 sirna

siRNA to inhibit ERCC6 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4557565
• NCBI GeneID: 2074
• NCBI Accession #: NP_000115.1
• NCBI GenBank Nucleotide #: NM_000124.3
• UniProt Accession #: Q03468; Q5W0L9; D3DX94
• Molecular Weight: 168,416 Da
• NCBI Official Full Name: DNA excision repair protein ERCC-6
• NCBI Official Synonym Full Names: excision repair cross-complementation group 6
• NCBI Official Symbol: ERCC6
• NCBI Official Synonym Symbols: CSB; CKN2; COFS; ARMD5; COFS1; RAD26; UVSS1
• NCBI Protein Information: DNA excision repair protein ERCC-6
• UniProt Protein Name: DNA excision repair protein ERCC-6
• Protein Family: DNA excision repair protein
• UniProt Gene Name: ERCC6
• UniProt Synonym Gene Names: CSB
• UniProt Entry Name: ERCC6_HUMAN

NCBI Description

This gene encodes a DNA-binding protein that is important in transcription-coupled excision repair. The encoded protein has ATP-stimulated ATPase activity, interacts with several transcription and excision repair proteins, and may promote complex formation at DNA repair sites. Mutations in this gene are associated with Cockayne syndrome type B and cerebrooculofacioskeletal syndrome 1. Naturally-occurring readthrough transcription occurs between this gene and the adjacent PGBD3 gene (GeneID:267004), and results in a fusion protein that shares sequence with the product of each individual gene. The readthrough locus is represented by GeneID:101243544. [provided by RefSeq, Mar 2013]

Uniprot Description

ERCC6: Essential factor involved in transcription-coupled nucleotide excision repair which allows RNA polymerase II-blocking lesions to be rapidly removed from the transcribed strand of active genes. Upon DNA-binding, it locally modifies DNA conformation by wrapping the DNA around itself, thereby modifying the interface between stalled RNA polymerase II and DNA. It is required for transcription-coupled repair complex formation. It recruits the CSA complex (DCX(ERCC8) complex), nucleotide excision repair proteins and EP300 to the at sites of RNA polymerase II- blocking lesions. Defects in ERCC6 are the cause of Cockayne syndrome type B (CSB). Cockayne syndrome is a rare disorder characterized by cutaneous sensitivity to sunlight, abnormal and slow growth, cachectic dwarfism, progeroid appearance, progressive pigmentary retinopathy and sensorineural deafness. There is delayed neural development and severe progressive neurologic degeneration resulting in mental retardation. Two clinical forms are recognized: in the classical form or Cockayne syndrome type 1, the symptoms are progressive and typically become apparent within the first few years or life; the less common Cockayne syndrome type 2 is characterized by more severe symptoms that manifest prenatally. Cockayne syndrome shows some overlap with certain forms of xeroderma pigmentosum. Unlike xeroderma pigmentosum, patients with Cockayne syndrome do not manifest increased freckling and other pigmentation abnormalities in the skin and have no significant increase in skin cancer. Defects in ERCC6 are the cause of cerebro-oculo-facio- skeletal syndrome type 1 (COFS1); also known as COFS syndrome or Pena-Shokeir syndrome type 2. COFS is a degenerative autosomal recessive disorder of prenatal onset affecting the brain, eye and spinal cord. After birth, it leads to brain atrophy, hypoplasia of the corpus callosum, hypotonia, cataracts, microcornea, optic atrophy, progressive joint contractures and growth failure. Facial dysmorphism is a constant feature. Abnormalities of the skull, eyes, limbs, heart and kidney also occur. Defects in ERCC6 are a cause of De Sanctis-Cacchione syndrome (DSC); also known as xerodermic idiocy. DSC is an autosomal recessive syndrome consisting of xeroderma pigmentosum associated with mental retardation, retarded growth, gonadal hypoplasia and sometimes neurologic complications. Defects in ERCC6 are the cause of susceptibility to age- related macular degeneration type 5 (ARMD5). A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Defects in ERCC6 are a cause of UV-sensitive syndrome type 1 (UVSS1). A rare autosomal recessive disorder characterized by photosensitivity and mild freckling but without neurological abnormalities or skin tumors. Patient exhibit a number of freckles, hypopigmented spots, telangiectases, and slightly dried skin in sun-exposed areas. Belongs to the SNF2/RAD54 helicase family.

Protein type: EC 3.6.4.-; EC 3.6.1.-; DNA repair, damage; Transcription regulation; Helicase

Chromosomal Location of Human Ortholog: 10q11.23

Cellular Component: nucleoplasm; transcription elongation factor complex; nucleolus; nucleus

Molecular Function: protein C-terminus binding; DNA-dependent ATPase activity; DNA helicase activity; protein binding; DNA binding; protein complex binding; protein tyrosine kinase activator activity; protein N-terminus binding; chromatin binding; ATP binding

Biological Process: transcription from RNA polymerase II promoter; response to superoxide; multicellular organism growth; positive regulation of RNA elongation; response to toxin; photoreceptor cell maintenance; RNA elongation from RNA polymerase I promoter; DNA repair; activation of JNK activity; response to UV-B; DNA damage response, signal transduction resulting in induction of apoptosis; nucleotide-excision repair; base-excision repair; transcription-coupled nucleotide-excision repair; pyrimidine dimer repair; response to gamma radiation; response to oxidative stress; regulation of RNA elongation; response to UV; activation of JNKK activity; response to X-ray

Disease: Lung Cancer; Cockayne Syndrome B; Macular Degeneration, Age-related, 5; De Sanctis-cacchione Syndrome; Uv-sensitive Syndrome 1; Cerebrooculofacioskeletal Syndrome 1